Hopp til innhold
Close

Get alerts of updates about «Buprenorphine versus methadone for pregnant women in opioid maintenance treatment (OMT)»

How often would you like to receive alerts from fhi.no? (This affects all your alerts)
Do you also want alerts about:

The email address you register will only be used to send you these alerts. You can cancel and delete your email address at any time by following the link in the alerts you receive.
Read more about the privacy policy for fhi.no

You have subscribed to alerts about:

  • Buprenorphine versus methadone for pregnant women in opioid maintenance treatment (OMT)

Oops, something went wrong...

... contact nettredaksjon@fhi.no.

... reload the page and try again-

Project

Buprenorphine versus methadone for pregnant women in opioid maintenance treatment (OMT) - project description

Published Updated

We will systematically summarise research on short- and long-term effects for mother, foetus and child of buprenorphine- versus methadone-based maintenance treatment during pregnancy.


Summary

It is unclear whether opioid dependent women in fertile age should be recommended buprenorphine or methadone when they enter opioid maintenance treatment (OMT). We will systematically summarise research on short- and long-term effects for mother, foetus and child of buprenorphine- versus methadone-based maintenance treatment during pregnancy.

See the full project description at Cristin for more information about results, researchers, contact information etc.

Project participants

Project leader

Hege Kornør, Avdeling for vurdering av tiltak, Norwegian Institute of Public Health

Project participants

Hilde Strømme, Avdeling for vurdering av tiltak, Norwegian Institute of Public Health
Kristin Thuve Dahm, Avdeling for vurdering av tiltak, Norwegian Institute of Public Health

Start

02.01.2019

End

24.05.2019

Status

Active

Project owner/ Project manager

Norwegian Institute of Public Health

Project manager

Hege Kornør

Participant at FHI

Kristin Thuve Dahm